Mono Mo A-Thyroid Transcription Factor (TTF-1) Cl 8G7G3/1: cost and payments to doctors
What Medicare Part D paid pharmacies for Mono Mo A-Thyroid Transcription Factor (TTF-1) Cl 8G7G3/1, and the payments that named it as the associated device or medical supply under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Agilent Technologies, Inc.?
Agilent Technologies, Inc. reported the most payments naming Mono Mo A-Thyroid Transcription Factor (TTF-1) Cl 8G7G3/1. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $61K
- Providers
- 0
- Transactions
- 4
- Average per transaction
- $15,358
The per-transaction average — $15,358 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. No payment naming this product was reported to an individual clinician. The Sunshine Act also covers payments to teaching hospitals as institutions — research funding, grants and device loans — and for this product that is all of it.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Agilent Technologies, Inc. | $61,433 | 100.0% |
Other products from Agilent Technologies, Inc.
The company that reported the most payments naming Mono Mo A-Thyroid Transcription Factor (TTF-1) Cl 8G7G3/1 also reports against these.
- PD-L1 IHC 22C3 pharmDx$2,929,893
- PD-L1 IHC 28-8 pharmDx$1,967,975
- PD-L1 IHC 22C3$1,526,154
- Actin$187,665
- BRCA1$187,665
- Cytokeratin$187,665
- Macrophage$187,665
- Melanosome$187,665
- Thyroid Transcription Factor$114,798
- FLEX Mono Mo A-Hu Melanosome Cl HMB45 RTU$87,421